Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.
Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A. Allen RA, et al. J Pharmacol Exp Ther. 2017 Jun;361(3):429-440. doi: 10.1124/jpet.116.237347. Epub 2017 Apr 25. J Pharmacol Exp Ther. 2017. PMID: 28442583
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B, Howat D, Lisle H, Holbrook M, James T, Gozzard N, Blease K, Hughes P, Kingaby R, Warrellow G, Alexander R, Head J, Boyd E, Eaton M, Perry M, Wales M, Smith B, Owens R, Catterall C, Lumb S, Russell A, Allen R, Merriman M, Bloxham D, Higgs G. Hughes B, et al. Br J Pharmacol. 1996 Jul;118(5):1183-91. doi: 10.1111/j.1476-5381.1996.tb15522.x. Br J Pharmacol. 1996. PMID: 8818342 Free PMC article.
CDP840: a novel inhibitor of PDE-4.
Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Allen R, Merriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA, Owens RJ. Perry MJ, et al. Cell Biochem Biophys. 1998;29(1-2):113-32. doi: 10.1007/BF02737831. Cell Biochem Biophys. 1998. PMID: 9631241
4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase.
Alexander R, Balasundaram A, Batchelor M, Brookings D, Crépy K, Crabbe T, Deltent MF, Driessens F, Gill A, Harris S, Hutchinson G, Kulisa C, Merriman M, Mistry P, Parton T, Turner J, Whitcombe I, Wright S. Alexander R, et al. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4316-20. doi: 10.1016/j.bmcl.2008.06.076. Epub 2008 Jun 28. Bioorg Med Chem Lett. 2008. PMID: 18625552
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R. Jamieson D, et al. Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28. Eur J Cancer. 2016. PMID: 27693888 Clinical Trial.
Fused thiophene derivatives as MEK inhibitors.
Laing VE, Brookings DC, Carbery RJ, Simorte JG, Hutchings MC, Langham BJ, Lowe MA, Allen RA, Fetterman JR, Turner J, Meier C, Kennedy J, Merriman M. Laing VE, et al. Bioorg Med Chem Lett. 2012 Jan 1;22(1):472-5. doi: 10.1016/j.bmcl.2011.10.105. Epub 2011 Nov 6. Bioorg Med Chem Lett. 2012. PMID: 22119475